Celgene (NASDAQ:CELG) is an American pharmaceutical stock which, in my opinion, has the most potential to grow out of any other large pharmaceutical company in the industry. Its blockbuster drug, Revlimid, has seen consistent double-digit revenue growth every year. CELG also has a large and strong pipeline with many different drugs which could become blockbuster drugs. The main 4 main drugs which are driving revenue for Celgene are Revlimid, Pomalyst, Otezla and Abraxane. Three of them have over a billion dollars in sales annually with Abraxane expected to exceed a billion dollars in 2017. These 4 revenue drivers are also all patent protected to at least 2022 (most of them are protected for longer than 2022). Revlimid will have patent protection until 2027 in the US.
